• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
Shionogi Received “2019 Award for Excellence in Corporate Disclosure” for Three Consecutive Year from the Securities Analysts Association of Japan (SAAJ)
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
M3 and Shionogi Joint Venture for Disease Solution - Establishment of Stream-I, Inc. -
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem
Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough - Favorable Results of Phase II Study Presented at the European Respiratory Society International Congress (ERS 2019)
【Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares (Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act and cancellation of treasury stocks pursuant to the provisions of Article 178 of the Companies Act)】
Shionogi to Present New Data at IDWeek 2019 - Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation
Shionogi to Announce Personnel Reassignment
Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2) in Children with Influenza
Shionogi Announces Positive Post-Exposure Prophylaxis Results for XOFLUZA® in Phase III Study (BLOCKSTONE) of Influenza Virus Infection in Household Members
Special Drug Use Survey for XOFLUZA® Announced at OPTIONS X - Analysis of Rate of Appearance and Clinical Course of Mutated Viruses at Position 38 in PA Protein for Influenza A/H1N1pdm and A/H3N2 Presented-
The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA® Clinical Studies
Shionogi Announces XOFLUZA® Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan.